ARA-290 (Cibinetide)

ARA-290, also called cibinetide or ARA 290, is a short peptide engineered from erythropoietin. It has been studied for its interaction with the innate repair receptor, a signaling complex associated with tissue protection and the resolution of inflammation. Research literature describes it as a nonerythropoietic peptide, meaning it was designed to retain tissue-protective signaling while lacking the blood cell stimulating activity of its parent molecule. It is sold by CoreX for laboratory research use only.

Research describes ARA-290 as selective for the innate repair receptor rather than the classical erythropoietin receptor. This selectivity is the basis for studying it in tissue-protective and anti-inflammatory signaling. It has also been investigated in research on small-fiber nerve signaling and discomfort associated with nerve stress, and one preclinical study reported that it relieves pathophysiological pain by targeting the TRPV1 channel, linking immune activity and nociception.

Human studies include a randomized double-blind pilot study in sarcoidosis patients with small fiber neuropathy symptoms and a phase II trial reporting improved metabolic control and neuropathic symptoms in type 2 diabetes. Preclinical work has examined cardiac inflammation and age-associated heart function, protection of transplanted islets, experimental autoimmune neuritis, and monocyte modulation in models of Alzheimer's-like pathology. These findings remain early and require confirmation in larger studies.

Human safety data for ARA-290 are limited, coming mainly from small pilot and phase II studies, and specific adverse events are not summarized in the cited study titles. A central design feature is that it is non-hematopoietic, so it is studied without the red blood cell stimulating activity associated with erythropoietin. Larger and longer studies would be needed to characterize its safety profile more fully.

Research protocols have used 1 to 8 mg per administration by subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. ARA-290 is supplied for laboratory research use only.